220 related articles for article (PubMed ID: 34006359)
1. Treatment of chylomicronemia.
Navarro Hermoso A; Valdivielso P
Clin Investig Arterioscler; 2021 May; 33 Suppl 2():75-79. PubMed ID: 34006359
[TBL] [Abstract][Full Text] [Related]
2. Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy.
Esan O; Wierzbicki AS
Drug Des Devel Ther; 2020; 14():2623-2636. PubMed ID: 32753844
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Gouni-Berthold I; Alexander VJ; Yang Q; Hurh E; Steinhagen-Thiessen E; Moriarty PM; Hughes SG; Gaudet D; Hegele RA; O'Dea LSL; Stroes ESG; Tsimikas S; Witztum JL;
Lancet Diabetes Endocrinol; 2021 May; 9(5):264-275. PubMed ID: 33798466
[TBL] [Abstract][Full Text] [Related]
4. Volanesorsen for treatment of familial chylomicronemia syndrome.
Lazarte J; Hegele RA
Expert Rev Cardiovasc Ther; 2021 Aug; 19(8):685-693. PubMed ID: 34261380
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS).
Jones A; Peers K; Wierzbicki AS; Ramachandran R; Mansfield M; Dawson C; Ochoa-Ferraro A; Soran H; Jenkinson F; McDowell I; Downie P; Hamilton P; Jones RD
Atherosclerosis; 2023 Jun; 375():67-74. PubMed ID: 37253281
[TBL] [Abstract][Full Text] [Related]
6. Severe Hypertriglyceridaemia and Chylomicronaemia Syndrome-Causes, Clinical Presentation, and Therapeutic Options.
Bashir B; Ho JH; Downie P; Hamilton P; Ferns G; Datta D; Cegla J; Wierzbicki AS; Dawson C; Jenkinson F; Delaney H; Mansfield M; Teoh Y; Miedzybrodzka Z; Haso H; Durrington PN; Soran H
Metabolites; 2023 Apr; 13(5):. PubMed ID: 37233662
[TBL] [Abstract][Full Text] [Related]
7. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.
Witztum JL; Gaudet D; Freedman SD; Alexander VJ; Digenio A; Williams KR; Yang Q; Hughes SG; Geary RS; Arca M; Stroes ESG; Bergeron J; Soran H; Civeira F; Hemphill L; Tsimikas S; Blom DJ; O'Dea L; Bruckert E
N Engl J Med; 2019 Aug; 381(6):531-542. PubMed ID: 31390500
[TBL] [Abstract][Full Text] [Related]
8. Monogenic hypertriglyceridemia and recurrent pancreatitis in a homozygous carrier of a rare APOA5 mutation: a case report.
Makhmudova U; Schulze PC; Lorkowski S; März W; Geiling JA; Weingärtner O
J Med Case Rep; 2024 Jun; 18(1):278. PubMed ID: 38872171
[TBL] [Abstract][Full Text] [Related]
9. Volanesorsen for treatment of patients with familial chylomicronemia syndrome.
Warden BA; Duell PB
Drugs Today (Barc); 2018 Dec; 54(12):721-735. PubMed ID: 30596391
[TBL] [Abstract][Full Text] [Related]
10. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score".
Moulin P; Dufour R; Averna M; Arca M; Cefalù AB; Noto D; D'Erasmo L; Di Costanzo A; Marçais C; Alvarez-Sala Walther LA; Banach M; Borén J; Cramb R; Gouni-Berthold I; Hughes E; Johnson C; Pintó X; Reiner Ž; van Lennep JR; Soran H; Stefanutti C; Stroes E; Bruckert E
Atherosclerosis; 2018 Aug; 275():265-272. PubMed ID: 29980054
[TBL] [Abstract][Full Text] [Related]
11. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial.
Witztum JL; Gaudet D; Arca M; Jones A; Soran H; Gouni-Berthold I; Stroes ESG; Alexander VJ; Jones R; Watts L; Xia S; Tsimikas S
J Clin Lipidol; 2023; 17(3):342-355. PubMed ID: 37100699
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of therapies for chylomicronemia.
Shamsudeen I; Hegele RA
Expert Rev Clin Pharmacol; 2022 Apr; 15(4):395-405. PubMed ID: 35762447
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia.
D'Erasmo L; Gallo A; Di Costanzo A; Bruckert E; Arca M
Expert Opin Pharmacother; 2020 Oct; 21(14):1675-1684. PubMed ID: 32646313
[TBL] [Abstract][Full Text] [Related]
14. Volanesorsen: A New Era in the Treatment of Severe Hypertriglyceridemia.
Kolovou G; Kolovou V; Katsiki N
J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207255
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome.
Cefalù AB; Giammanco A; Noto D; Spina R; Cabibi D; Barbagallo CM; Averna M
Endocrine; 2021 Feb; 71(2):344-350. PubMed ID: 33006726
[TBL] [Abstract][Full Text] [Related]
16. Rare Variants in Triglycerides-Related Genes Increase Pancreatitis Risk in Multifactorial Chylomicronemia Syndrome.
Paquette M; Amyot J; Fantino M; Baass A; Bernard S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3473-e3482. PubMed ID: 34019660
[TBL] [Abstract][Full Text] [Related]
17. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia.
Baass A; Paquette M; Bernard S; Hegele RA
J Intern Med; 2020 Apr; 287(4):340-348. PubMed ID: 31840878
[TBL] [Abstract][Full Text] [Related]
18. Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.
Blom DJ; O'Dea L; Digenio A; Alexander VJ; Karwatowska-Prokopczuk E; Williams KR; Hemphill L; Muñiz-Grijalvo O; Santos RD; Baum S; Witztum JL
J Clin Lipidol; 2018; 12(5):1234-1243.e5. PubMed ID: 30318066
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome.
Chaudhry R; Viljoen A; Wierzbicki AS
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):589-598. PubMed ID: 29842811
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
